
Viz.ai Announces Agreement with Bristol Myers Squibb to Enable Earlier Detection and Management...
Press & NewsViz.ai has submitted a de novo classification request to the FDA for a new AI algorithm intended to identify and...
DownloadWhite Paper
Read this interview with Dr. Chris Mansi, CEO of Viz.ai, on how the company's AI software is becoming a standardsetter for broader patient engagement with big pharma from advancing clinical trials to launching the next generation of specialty medicines.
Viz.ai has submitted a de novo classification request to the FDA for a new AI algorithm intended to identify and...
Download